Eris, BA.2.86: Do I need to worry about COVID again?
Send a link to a friend
[August 21, 2023]
By Deena Beasley and Nancy Lapid
(Reuters) - The World Health Organization and the U.S. Centers for
Disease Control and Prevention are tracking a new, highly mutated
lineage of the virus that causes COVID-19.
Six cases in four countries have been detected since late July.
Scientists are keeping an eye on the new lineage, named BA.2.86, because
it has 36 mutations that distinguish it from the currently-dominant
XBB.1.5 variant.
So far there is no evidence that BA.2.86 spreads faster or causes more
serious illness than previous versions. The CDC said its advice on
protecting yourself from COVID remains the same.
What is new about COVID?
COVID infections and hospitalizations have been rising in the U.S.,
Europe and Asia, with more cases in recent months attributed to the EG.5
"Eris" subvariant, a descendant of the Omicron lineage that originally
emerged in November 2021.
Over the past few days, public health authorities have documented one
case each of BA.2.86 in the United States, the UK, and Israel, and three
cases in Denmark.
What do scientists say about BA.2.86?
BA.2.86 stems from an "earlier branch" of the coronavirus, so it differs
from the variant targeted by current vaccines, explained Dr. S. Wesley
Long, medical director of diagnostic microbiology at Houston Methodist
Hospital.
He said it remains to be seen whether BA.2.86 will be able to
out-compete other strains of the virus or have any advantage in escaping
immune responses from prior infection or vaccination.
But many countries have drastically reduced testing of patients and
their efforts to analyze the genomes of the viruses causing new COVID
cases. In that situation, the trajectory of BA.2.86 "doesn't look good
right now," given the speed at which new cases are being identified,
said Dr. Eric Topol, a genomics expert and director of the Scripps
Research Translational Institute in La Jolla, California.
Its many mutations make BA.2.86 "radically different in its structure"
compared to earlier variants, Topol said.
The main question, he added, is whether BA.2.86 will turn out to be
highly transmissible.
Do the new variants make people sicker?
[to top of second column]
|
A nurse fills up syringes with the
coronavirus disease (COVID-19) vaccines for residents who are over
50 years old and immunocompromised and are eligible to receive their
second booster shots in Waterford, Michigan, U.S., April 8, 2022.
REUTERS/Emily Elconin/File Photo
U.S. emergency department visits and
hospitalizations for COVID remain low, but have been rising since
early July, according to data on the CDC website. So far, however,
doctors have been reporting that patients seen in recent weeks, as
the Eris variant has been spreading, are not as sick as those they
treated during earlier waves of the pandemic.
Wider spread of BA.2.86 would likely cause more illness and death in
vulnerable populations, Topol said.
It is too soon to know whether BA.2.86 will cause more-severe
illness.
"Based on the available evidence, we do not yet know what risks, if
any, (BA.2.86) may pose to the public's health beyond what has been
seen with other currently circulating lineages," a CDC spokesperson
said.
Will vaccines protect against new variants?
Due to the waning of the pandemic, it may have been a year or more
since many people were either previously infected or vaccinated
against COVID.
"The vaccine is still going to provide you great defense against
illness and death," Long said.
Updated COVID booster shots now being developed have been designed
to target the Omicron subvariant XBB.1.5.
Moderna said preliminary trial data suggest its latest version of
the vaccine shows promise against Eris and a related variant called
Fornax, which has begun to circulate in the U.S.
Pfizer Inc has said its updated COVID-19 shot showed neutralizing
activity against the Eris subvariant in a study conducted on mice.
(Reporting By Deena Beasley and Nancy Lapid; Editing by David
Gregorio)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |